RT Journal Article
SR Electronic
T1 Could Chinese cardiovascular chronic conditions patients gain benefits from pharmaceutical services? A multilevel meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.25.24310734
DO 10.1101/2024.07.25.24310734
A1 Deng, Zhijie
A1 Chen, Fanglu
A1 Peng, Shunshun
A1 Gui, Lin
A1 Huang, Yangjin
A1 Chen, Jing
A1 Wei, Anhua
A1 Ding, Yufeng
YR 2024
UL http://medrxiv.org/content/early/2024/07/25/2024.07.25.24310734.abstract
AB Background The value of pharmaceutical services for Chinese patients with cardiovascular chronic conditions was not recognized.Aim To investigate the comprehensive value of pharmaceutical services in China and find factors influencing patient benefits.Design and setting This was a systematic review with multilevel meta-analysis of 183 randomized control trials focusing on the benefits of pharmaceutical services for patients with cardiovascular chronic conditions in China.Methods English databases (PubMed, EMBASE, the Cochrane Library) and Chinese databases (China National Knowledge Infrastructure, WanFang database) were searched from database inception to March 27, 2023 for studies focusing on the comparation of benefits between pharmaceutical services and usual care.Results Our analysis of 187 studies involving 23,895 patients demonstrated significant benefits of pharmaceutical services, particularly in reducing readmission (OR: 0.32; 95%CI: 0.2 to 0.52; I2=50.12%), mitigating ADR (OR: 0.28; 95%CI: 0.24 to 0.33; I2=18.07%), and improving patient adherence. However, no benefit was observed in terms of mortality rate and the cost of hospitalization and medication and the risk of bias was generally existed among the included studies.Conclusions This study highlights the significant benefits of pharmaceutical services for clinical outcomes and adherence among Chinese patients with cardiovascular chronic conditions. However, the benefits in terms of economic outcomes remain unclear. The influence of population-specific factors, such as disease and age, underscores the need for context-specific and disease- tailored studies to provide precise evidence regarding the advantages of pharmaceutical services. And our findings provide some new ideas for the subsequent research and design, standard formulation and policy implementation.How this fits in Previous assessments showed clinical benefits of pharmaceutical services but were unclear about other benefits and didn’t consider patient characteristics or contexts. There is no standardized system for pharmaceutical services in China. Our meta-analysis found clear clinical benefits for patients with cardiovascular chronic conditions and showed that age negatively impacts adherence, and medication costs vary by disease type. This study is the first to analyze comprehensive benefits for Chinese patients, highlighting the importance of considering patient characteristics in pharmaceutical services.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=414180 Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors